Open AccessSuccessful Treatment of Chronic Antibody-Mediated Rejection With IVIG and Rituximab in Pediatric Renal Transplant Recipients
Author(s) -
Heiko Billing,
Susanne Rieger,
Jörg Ovens,
Caner Süsal,
Anette Melk,
Rüdiger Waldherr,
Gerhard Opelz,
Burkhard Tönshoff
Publication year - 2008
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e3181880b35
Subject(s) - rituximab , medicine , renal function , regimen , urology , gastroenterology , antibody , transplantation , cd20 , immunology
Chronic antibody-mediated rejection (CAMR) of renal allografts has recently been recognized as a defined nosologic entity. The outcome of CAMR is poor; there is no established treatment protocol for this condition. We therefore initiated a pilot study on treatment of CAMR with an antihumoral regimen consisting of high-dose intravenous immunoglobulin (IVIG) and the chimeric anti-CD20 antibody rituximab.